Phibro Animal Health Corporation $PAHC Position Reduced by Rhumbline Advisers

Rhumbline Advisers lessened its position in Phibro Animal Health Corporation (NASDAQ:PAHC) by 3.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 73,677 shares of the company’s stock after selling 2,905 shares during the period. Rhumbline Advisers owned approximately 0.18% of Phibro Animal Health worth $1,574,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Phibro Animal Health by 0.4% during the first quarter. Vanguard Group Inc. now owns 1,521,520 shares of the company’s stock valued at $32,500,000 after acquiring an additional 6,784 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Phibro Animal Health by 0.5% in the 1st quarter. Acadian Asset Management LLC now owns 782,939 shares of the company’s stock valued at $16,713,000 after acquiring an additional 4,144 shares during the last quarter. Nuveen Asset Management LLC grew its position in shares of Phibro Animal Health by 21.4% in the 4th quarter. Nuveen Asset Management LLC now owns 588,001 shares of the company’s stock valued at $12,348,000 after purchasing an additional 103,618 shares during the period. Nuveen LLC acquired a new position in Phibro Animal Health during the 1st quarter worth approximately $10,312,000. Finally, Invesco Ltd. boosted its holdings in shares of Phibro Animal Health by 92.3% in the 1st quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock valued at $8,282,000 after buying an additional 186,087 shares during the last quarter. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Trading Up 5.1%

Shares of PAHC stock opened at $40.54 on Friday. The stock’s 50-day moving average price is $32.68 and its 200-day moving average price is $25.96. The company has a current ratio of 2.76, a quick ratio of 1.25 and a debt-to-equity ratio of 2.46. Phibro Animal Health Corporation has a 12-month low of $16.16 and a 12-month high of $41.57. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of 34.36, a price-to-earnings-growth ratio of 1.15 and a beta of 0.89.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.05. The firm had revenue of $378.70 million during the quarter, compared to analyst estimates of $362.24 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. Equities research analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 24th. Shareholders of record on Wednesday, September 3rd will be paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 3rd. Phibro Animal Health’s dividend payout ratio (DPR) is 40.68%.

Analysts Set New Price Targets

Several analysts recently weighed in on PAHC shares. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 28th. BNP Paribas raised Phibro Animal Health to a “hold” rating in a research report on Monday, June 16th. Morgan Stanley set a $34.00 target price on Phibro Animal Health in a research note on Thursday, August 28th. BNP Paribas Exane upgraded Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 price objective on the stock in a research note on Monday, June 16th. Finally, JPMorgan Chase & Co. upgraded Phibro Animal Health from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $25.00 to $35.00 in a research note on Monday, July 7th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $28.40.

Insiders Place Their Bets

In other news, CEO Jack Bendheim sold 14,080 shares of Phibro Animal Health stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $40.33, for a total transaction of $567,846.40. Following the sale, the chief executive officer owned 45,400 shares of the company’s stock, valued at approximately $1,830,982. The trade was a 23.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 50.07% of the stock is owned by company insiders.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.